Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations-Reference-Cited by-同舟云学术

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

Published:2015-08-20 Issue:8 Volume:373 Page:726-736
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Hyman David M.¹,Puzanov Igor¹,Subbiah Vivek¹,Faris Jason E.¹,Chau Ian¹,Blay Jean-Yves¹,Wolf Jürgen¹,Raje Noopur S.¹,Diamond Eli L.¹,Hollebecque Antoine¹,Gervais Radj¹,Elez-Fernandez Maria Elena¹,Italiano Antoine¹,Hofheinz Ralf-Dieter¹,Hidalgo Manuel¹,Chan Emily¹,Schuler Martin¹,Lasserre Susan Frances¹,Makrutzki Martina¹,Sirzen Florin¹,Veronese Maria Luisa¹,Tabernero Josep¹,Baselga José¹

Affiliation:

1. From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1502309

Cited by 1515 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study;Future Oncology;2024-09-03

3. COVID-19 platform trials: insight and lessons in clinical trial design;COVID-19: An Update;2024-09-01

4. BRAF-Mutant Metastatic Colorectal Cancer: Current Evidence, Future Directions, and Research Priorities;Clinical Colorectal Cancer;2024-09

5. Real-world experience with targeted therapy in patients with histiocytic neoplasms in the Netherlands and in Belgium;Blood Neoplasia;2024-09